Further to the results of prior studies published last year, Almirall, the international pharmaceutical company based in Spain, announced new Phase II multi-dose study results demonstrating that its novel once-daily, inhaled, long-acting beta-agonist (LABA) -LAS100977-, for the treatment of bronchoconstriction in asthmatic patients, shows fast-acting and 24-hour efficacy, as well as a good safety and tolerability profile in patients during multiple dose administrations.
(more...)